51 results about "Large cell lung cancer" patented technology

The invention relates to medicine application of 20(S)-ginsenoside Rg3, in particular to application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating a non-small cell lung cancer. In the invention, selecting a human non-small cell lung cancer cell strain (A549 lung adenocarcinoma, H460 large cell lung cancer and LTEP-78 lung squamous carcinoma) to be inoculated under the skin of a naked mouse, and observing the influence of the SPG-Rg3 on the non-small cell lung cancer; and carrying out CD34 immunohistochemistry staining and TUNEL immunofluorescence staining on tumor tissues, and observing the influence of the SPG-Rg3 on tumor angiogenesis and apoptosis. The inclusion proves that the 20(S)-ginsenoside Rg3 can remarkably inhibit the growth of the non-small cell lung cancer, has the action mechanism related with the promotion of the tumor apoptosis and the inhibition of the tumor angiogenesis and unobvious cooperation action when being combined with cyclophosphamide for application, and can be used for the clinical chemotherapy of the non-small cell lung cancer.

The invention provides a method for preparing bile and patchouli rhinitis tablets. The rhinitis tablets are prepared from 15g of porcine bile paste, 560g of patchouli, 560g of dahurian angelica, 450g of cocklebur fruit, 375g of centipeda, 250g of schizonepeta, 250g of honeysuckle, 250g of wild chrysanthemum and 1.5g of menthol serving as raw medicaments by adopting supercritical extraction and microwave extraction, so that the cocklebur fruit content is greatly improved. The invention also provides application of the bile and patchouli rhinitis tablets in preparation of a medicament for inhibiting propagation of human large cell lung cancer NC1-H460 cells.

The invention discloses a method for preparing diaporthein B and application of the diaporthein B to the preparation of antitumor medicaments. In the method, the diaporthein B with antitumor activity is separated from a liquid fermentation culture of a marine fungus, namely Eutypella scoparia FS26. The method has the advantages that culture conditions are mild, a culture medium is easy to prepare, fermentation time is short, separation and purification steps are simple, the mass production can be realized under manual control conditions and the like, and the problem of medicament sources can be solved more conveniently. Through the experiment, IC50 values of the diaporthein B for a glioma cell SF-268, a breast cancer cell MCF-7 and a large-cell lung cancer cell NCI-H460 are 92mu M, 44mu M and 9.9mu M respectively, the diaporthein B has remarkable antitumor activity, and IC50 values of a positive control, namely cis-platinum for the three tumor cell strains are 4.6mu M, 4.1mu M and 3.0mu M respectively. Therefore, a candidate compound is provided for researching and developing novel antitumor medicaments, and a scientific evidence is provided for developing and utilizing natural active substances which are derived from marine microorganisms.

The invention discloses a bladder cancer cell inhibitor and a preparation method thereof. The complex dichloro.2.[4.(methoxy).phenyl]imidazo[4, 5.f][1, 10].phenanthroline.R, R.platinum cyclohexanediamine (II) has chirality. With 1,10-phenanthroline.5,6.dione and 4.methoxybenzaldehyde as raw materials, 2.[4.(methoxy).phenyl]imidazo[4, 5.f][1, 10].phenanthroline is prepared; potassium chloroplatinite is added to prepare 2.[4.(methoxy).phenyl]imidazo[4, 5.f][1, 10].phenanthroline.dichloro platinum (II); and finally, cyclohexanediamine is added to obtain the product bladder cancer cell inhibitor. The complex has excellent anti-tumor activity and can be applied to the drugs against bladder cancer and human large-cell lung cancer cells.

The invention relates to a reagent kit for lung cancer detection. The reagent kit comprises a reagent for specific detection of miRNA (micro ribonucleic acid)-6070. The reagent kit can effectively detect a large cell lung cancer and quickly achieve quantitative detection of miRNA, and therefore achieves the purpose of quickly and effectively detecting the large cell lung cancer.

The invention discloses application of Lycojaponicumin A in preparation of medicaments for treating lung cancer. The compound shows good anti-lung cancer activity, can be used for preparing anti-lung cancer medicaments, and belongs to the technical field of new application of medicaments. The Lycojaponicumin A can prominently inhibit non-small cell lung cancer cells A549, large cell lung cancer cells NCI-H460, lung squamous cancer cells HTB-8 and human lung flat epithelial cancer cells QG-5 cultured in vitro, has a low inhibiting effect on human normal liver cells LO2 and peripheral blood lymphocytes, and shows obvious selectivity. The application of the Lycojaponicumin A in preparation of the medicaments for treating the lung cancer is made public for the first time; and because the skeleton type is completely novel, the Lycojaponicumin A has an unexpectedly strong lung cancer cell inhibiting activity.

The invention belongs to the field of medicines, and particularly relates to a novel arylurea-containing 4-arylpyran derivative of a structure as shown in a general formula (I) as shown in the specification and application of the novel arylurea-containing 4-arylpyran derivative of the structure as shown in the general formula (I) as shown in the specification. The derivative is as shown in the general formula (I) as shown in the specification, and can be used medicinally when salts are formed by adding acids into the derivative, wherein R and Ar are defined in the specification. Results of pharmacological activity screening of the compound show that the compound has significant inhibiting effects on human colon cancer cells HT-29, human lung adenocarcinoma cell A549 and human large cell lung cancer cells H460, and has good anti-tumor medicine development and application prospects.

The invention discloses application of Chukrasone A in preparation of medicaments for treating lung cancer. The compound shows excellent activity for resisting lung cancer, can be used for preparing medicaments for resisting lung cancer, and belongs to the technical field of novel application of medicaments. Chukrasone A can remarkably inhibit in vitro cultured non-small cell lung cancer cells A549, large cell lung cancer cells NCI-H460, squamous cell lung carcinoma cells HTB-8 and human lung epidermoid carcinoma QG-5, but hardly has inhibition effects on human normal hepatocytes LO2 and peripheral blood lymphocytes, and shows a remarkable selectivity. The application of Chukrasone A in preparation of medicaments for treating lung caner is disclosed for the first time, and the frame type belongs to a brand-new frame type, so that the inhibition activity of the Chukrasone A to lung cancer cells is unexpectedly strong.

The invention relates to an imidazopyridine mercapto-acetamide derivative shown as a general formula I or a medicinal salt thereof, a pharmaceutical composition containing the compound, and application of the pharmaceutical composition to the preparation of a human solid tumor resistant medicament. Human solid tumors include human large cell lung cancer, human liver cancer, human colon tumor and human breast cancer. The general formula I is shown in the description.

The invention relates to the nucleic acid and polypeptide sequences of two novel human GAK-related gene variants.

The invention also relates to the process for producing the polypeptides of the variants.

The invention further relates to the use of the nucleic acid and polypeptide sequences of the gene variants in diagnosing diseases associated with the deficiency of GAK gene, in particular, iron homeostasis impairment-related diseases or non-small cell lung cancer (NSCLC), e.g. large cell lung cancer.

The invention discloses an application of Houttuynoid A in preparing drugs for treating lung cancer. As a compound, the Houttuynoid A shows high anti-lung cancer activity, can be used for preparing the anti-lung cancer drugs and belongs to the technical field of new uses of the drugs. The Houttuynoid A is capable of remarkably inhibiting non-small cell lung cancer cells A549, large cell lung cancer cells NCI-H460, lung squamous cancer cells HTB-8 and human lung epidermoid carcinoma cells QG-5, but is smaller in effect of inhibiting human normal hepatocytes LO2 and peripheral blood lymphocytes, i.e. obvious selectivity is shown. The application of the Houttuynoid A in preparing the drugs for treating the lung cancer is disclosed for the first time. Moreover, the skeleton type of the Houttuynoid A is fire-new, and how strong the inhibitory activity of the Houttuynoid A on the lung cancer cells is unexpected.

The invention discloses application of Linderolide H in the preparation of lung cancer drugs; the compound exhibits good lung cancer resisting activity, is applicable to the preparation of lung cancer drugs and belongs to the technical field of novel applications of drugs. Linderolide H can significantly inhibit non-small cell lung cancer cells A549, large cell lung cancer cells NCI-H460, lung squamous carcinoma cells HTB-8 and human lung squamous carcinoma cells QG-5 cultured in vitro, but exhibit low inhibitory action on human normal liver cell LO2 and peripheral blood lymphocyte, and shows significant selectivity; the application of Linderolide H in the preparation of lung cancer drugs is disclosed herein for the first time; since a framework is of brand-new type, the inhibitory activity for lung cancer cells is unexpectedly high.